Congratulations to Chengdu Shibeikang Biomedical Technology Co., Ltd. for Being Recognized as a ‘Sichuan Innovative SME’ - SBK Continues to Drive Development Through Innovation

Recently, Chengdu Municipal Bureau of Economy and Information Technology released the Public Notice of Innovative SMEs List for Q4 2022. After a rigorous evaluation process, which included an enterprise application, a recommendation from the Chengdu High-Tech Zone, and a thorough review by the Chengdu Municipal Bureau of Economy and Information Technology, Chengdu SBK Biomedical Technology Co., Ltd. was successfully recognized as a “Sichuan Innovative SME” for its strong technological innovation capabilities, rapid innovative development, and expertise in innovative drug R&D. 

It is reported that to standardize the evaluation and recognition of high-quality SMEs in the province, strengthen the gradient cultivation and management of high-quality SMEs, and promote the high-quality development of SMEs, the Sichuan Provincial Department of Economy and Information Technology formulated the Implementation Plan for Gradient Cultivation and Management of High-Quality SMEs in Sichuan Province based on the Interim Measures for Gradient Cultivation and Management of High-Quality SMEs (MIIT Enterprise [2022] No. 63) issued by the Ministry of Industry and Information Technology. The evaluation indicators for innovative SMEs include three categories and six indicators: innovation capability, growth potential, and specialization. 

Chengdu Shibeikang Biomedical Technology Co., Ltd. is a high-tech enterprise integrating drug R&D and sales. The company focuses on both the research and development (R&D) and commercialization of innovative drugs, particularly in the fields of cardiovascular and cerebrovascular diseases. The company’s R&D team comprises over 80% of its workforce, with more than 30% holding master’s and doctoral degrees. Additionally, two of the company’s team members are recognized as provincial and municipal top talents. In 2021, SBK was honored as part of Chengdu’s prestigious “Rong Piao Plan”, an initiative that recognizes the city’s leading innovation and entrepreneurship teams. SBK fosters a strong academic and innovative environment with more than 10 innovative drug candidates currently in development. Over the years, the company has made significant technological advancements, filing for over 80 invention patents, including 7 PCT patents, and has been granted 9 invention patents to date. 

Looking ahead, SBK remains committed to its core values of “Empowering Better Health Through Inclusive Care and Support”. With a patient-centered and clinically-driven approach, the company will continue to leverage its integrated innovation platform for drug metabolism differentiation to tackle more clinical challenges.